Search

Author/Creator Tinker, A.V.

1. Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC). (February 2017)

Authors:
Oaknin, A.; Oza, A.; Tinker, A.V.; Ray-Coquard, I.; Coleman, R.; O'Malley, D.; Shapira-Frommer, R.; Leary, A.; Chen, L.M.; Provencher, D.; Ma, L.; Brenton, J.; Balmaña, J.; Giordano, H.; Maloney, L.; Goble, S.; Rolfe, L.; McNeish, I.; Swisher, E.; Kristeleit, R.S.
Journal:
European journal of cancer
Issue:
Volume 72(2017)Supplement 1
Page Start:
S95
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer. (December 2016)

Authors:
Lin, K.; Tinker, A.V.; Kondrashova, O.; Ho, G.; Wakefield, M.; Coleman, R.L.; O'Malley, D.M.; Floquet, A.; Sun, J.; Maloney, L.; Giordano, H.; Harding, T.; Raponi, M.; McNeish, I.A.; Swisher, E.; Scott, C.L.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S13
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search